¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"non Hodgkin lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adult T-cell leukemia/lymphoma
    ¼ºÀÎT¼¼Æ÷¹éÇ÷º´/¸²ÇÁÁ¾
  • anaplastic large cell lymphoma
    ¿ªÇü¼ºÅ«¼¼Æ÷¸²ÇÁÁ¾
  • Burkitt¡¯s lymphoma
    ¹öŶ¸²ÇÁÁ¾
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
  • diffuse large B-cell lymphoma
    ±¤¹üÀ§Å«B¼¼Æ÷¸²ÇÁÁ¾
  • enteropathy-type T-cell lymphoma
    À庴ÁõÇüT¼¼Æ÷¸²ÇÁÁ¾
  • follicular lymphoma
    ¼ÒÆ÷¸²ÇÁÁ¾
  • hepatosplenic T-cell lymphoma
    °£ºñÀåT¼¼Æ÷¸²ÇÁÁ¾
  • histiocytic lymphoma
    Á¶Á÷±¸¸²ÇÁÁ¾
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • immunoblastic lymphoma
    ¸é¿ª¸ð¼¼Æ÷¸²ÇÁÁ¾, ¸é¿ª¸ð±¸¸²ÇÁÁ¾
  • lymphoblastic lymphoma
    ¸²ÇÁ¸ð±¸¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma staging
    ¸²ÇÁÁ¾º´±â°áÁ¤
  • mantle cell lymphoma
    ¿ÜÅõ¼¼Æ÷¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • non-healing granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾
  • non enhanced image
    ºñÁ¶¿µÁõ°­¿µ»ó
  • non-rapid eye movement
    ºñ±Þ¼Ó¾È±¸¿îµ¿
  • non compos mentis
    ½É½Å»ó½Ç»óÅÂ
  • non-lysosomal proteinase
    ºñ¸®¼Ò¼Ø´Ü¹éºÐÇØÈ¿¼Ò
  • non-proprietary name
    ÀϹݸí
  • non-vibrating tinnitus
    ºñÁøµ¿±Í¿ï¸², ºñÁøµ¿À̸í
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adult t-cell leukemia/lymphoma
    ¼º¼÷ T-¼¼Æ÷ ¹éÇ÷º´/¸²ÇÁÁ¾(à÷âÙ¡­á¬øà ÛÜúìÜ»/¡­ðþ)
  • giant follicular lymphoma
    °Å´ë¿©Æ÷¼º ¸²ÇÁÁ¾.
  • immunoblastic lymphoma
    ¸é¿ª ¸ð¼¼Æ÷ ¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • histiocytic lymphoma
    Á¶Á÷±¸¸²ÇÁÁ¾
  • immunoblastic lymphoma
    ¸é¿ª ¸ð¼¼Æ÷ ¸²ÇÁÁ¾
  • intestinal lymphoma
    À帲ÇÁÁ¾.
  • large cell anaplastic lymphoma
    ´ë¼¼Æ÷ ÅðÇ༺ ¸²ÇÁÁ¾
  • large cell lymphoma
    ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • leukemia/lymphoma
    ¹éÇ÷º´/¸²ÇÁÁ¾(ÛÜúìÜ»/¡­ðþ)
  • lymphoepithelioid lymphoma
    ¸²ÇÁÇ¥ÇÇ¾ç ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾.
  • lymphoma
    ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma cells
    ¸²ÇÁÁ¾¼¼Æ÷(¡­á¬øà)
  • lymphoma, Burkitts
    ¹öŶƮ ¸²ÇÁÁ¾
  • lymphoma,burkitts
    ¹öŶ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma,follicular
    ¿©Æ÷¼º¸²ÇÁÁ¾(æ¤øààõ¡­ðþ)
  • lymphoma,large cell, diffuse
    ´ë¼¼Æ÷¼º ¸²ÇÁÁ¾(ÓÞá¬øààõ ¡­ðþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
NANB non-A, non-B [hepatitis]
NANBH non-A, non-B hepatitis
non-REM non-rapid eye movement [sleep]
HD   1) Hodgkin's Disease
  2) Hemo-Dialysis
  3) High Density
&...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
T-NHL T cell non-Hodgkin's lymphoma
hgNHL high grade Non-Hodgkin's lymphoma
NHL non-Hodgkin malignant lymphoma
HL Hodgkin lymphoma
AIDS-NHL AIDS-related non-Hodgkin lymphomas
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • conditio sine qua non
    Àý´ë ÇÊ¿ä Á¶°Ç
  • myelinated non-nociceptive afferent
    À¯¼öÃÊ ºñÄ§ÇØ¼ö¿ë¼º ±¸½É ½Å°æ, À¯¼öÃÊ ºñÀ¯Çؼö¿ë¼º ±¸½É ½Å°æ
  • non inbred
    ºñ±ÙÄ£±³¹è°è µ¿¹°
  • non odontogenic cyst
    ºñ Ä¡¼º ³¶
  • non- pressure impression
    ¹«¾Ð Àλó
  • non-adjustable articulator
    ºñÁ¶Àý¼º ±³ÇÕ±â
    ȯÀÚÀÇ ÇϾǰñ ¿îµ¿À» ¿ÏÀüÈ÷ ÀçÇö½Ãų ¼ö ¾ø´Â ±³ÇÕ±â.
  • non-anatomical porcelain teeth
    ºñÇØºÎÇÐÀû µµÄ¡
    ÀÚ¿¬Ä¡¿Í Á¶±Ýµµ À¯»çÇÏÁö ¾Ê°í ±âÇÏÇÐÀûÀ¸·Î ¼ºÇüµÈ ÇüŸ¦ °¡Áö´Â ´õ¿íÀÌ ÃÑÀÇÄ¡ÀÇ ±³ÇÕ¿¡ Á¶È­µÇµµ·Ï ¸¸µé¾îÁø ±¸Ä¡ºÎ¿ëÀÇ ÀΰøÄ¡.
  • non-caseating epithelioid cell granulomata
    ºñ°Ç¶ô¼º À¯»óÇÇ ¼¼Æ÷ À°¾ÆÁ¾
  • non-centric cusp tip
    ºñÁ᫐ ±³µÎÁ¤
  • non-cleft side
    ºñ±¸°³¿­Ãø
  • non-dental pain
    ºñÄ¡¼º ÅëÁõ
  • non-enhanced image
    ºñÁ¶¿µ Áõ°­ ¿µ»ó
  • non-inflammatory
    ºñ¿°Áõ¼º
  • non-injury controlled population
    ºñ¿Ü»ó¼º ȯÀÚ
  • non-invasive
    ºñ°üÇ÷Àû, ºñħ¹ü¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
disease, hodgkin's A type of lymphoma (cancer of the lymphatic system). The most common symptom is painless swelling of the lymph nodes in the neck, underarm, or groin. Hodgkin's disease is diagnosed when abnormal tissue is detected by a pathologist after a biopsy of an enlarged lymph node. Treatment usually includes radiation therapy or chemotherapy. Regular follow-up examinations are important after treatment. Patients treated for Hodgkin's disease have an increased risk of developing other types of cancer later in life, especially leukaemia.
A disease of the lymph nodes named after the English physician Thomas Hodgkin (1798-1866) who discovered it.
(12 Dec 1998)
abortifacient agents, non-steroidal Non-steroidal chemical compounds with abortifacient activity.
(12 Dec 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
analgesics, non-narcotic Drugs that have principally analgesic, antipyretic, and anti-inflammatory actions. They do not bind to opioid receptors and are not classified under the controlled substances act.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
auctorum non Not of authors.
(09 Jan 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
chromosomal proteins, non-histone Nucleoproteins which in contrast to histones are acid insoluble. They are involved in chromosomal functions; e.g. They bind selectively to DNA, stimulate transcription resulting in tissue-specific RNA synthesis and undergo specific changes in response to various hormones or phytomitogens.
(12 Dec 1998)
prescriptions, non-drug Written directions for the preparation, administration, or application of a non-drug remedy. This includes prescriptions for corrective lenses, self-help and orthopedic devices, and physical therapy and rehabilitation measures.
(12 Dec 1998)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
histiocytosis, non-langerhans-cell Group of disorders which feature accumulations of active histiocytes and lymphocytes, but where the histiocytes are not langerhans cells. The group includes haemophagocytic lymphohistiocytosis, infection-associated haemophagocytic syndrome, sinus histiocytosis, xanthogranuloma, reticulohistiocytoma, juvenile xanthoma, xanthoma disseminatum, as well as the lipid storage diseases (sea-blue histiocyte syndrome and niemann-pick disease).
(12 Dec 1998)
nodular non-X histiocytosis A rare recurring generalised eruption in adults of flesh coloured or erythematous papules remaining localised to the skin and consisting of dermal nodules of mononuclear histiocytes that do not stain for lipid.
Synonym: nodular non-X histiocytosis.
(05 Mar 2000)
non-arcon articulator An articulator with the equivalent condylar guides attached to the lower member and the hinge axis to the upper member.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non possumus
    ¹«´É·Â(ºÒ´É)ÀÇ ½Åû
  • non prosequitur
    (¼Ò¼ÛÀýÂ÷¸¦ Ÿ¸È÷ ÇÏ´Â ¿ø°í¿¡ ´ëÇÑ)ÆÐ¼ÒÆÇ°á
  • non seq.
    non sequitur
  • non sequitur
    ±×¸©µÈ °á·Ð
  • non troppo
    Áö³ªÄ¡Áö ¾Ê°Ô;¾Ë¸Â°Ô
  • non-
    ¾Ê´Ù;¾Æ´Ï´Ù
  • non-
    (ÀÚÀ¯·ÎÀÌ ¸í»ç,Çü¿ë»ç,ºÎ»ç¿¡ ºÙ¿©¼­);ºñ;ºÒ;¹«ÀÇ ¶æÀ» ³ªÅ¸³¿
  • sine qua non
    ÇÊ¿ä Á¶°Ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á